Comparative Pharmacology
Head-to-head clinical analysis: HEXALEN versus THIOTEPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXALEN versus THIOTEPA.
HEXALEN vs THIOTEPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
0.3-0.4 mg/kg intravenously every 1-4 weeks; or 0.5-1 mg/kg intravenously every 2-4 weeks (commonly 60 mg/m² IV every 1-4 weeks).
None Documented
None Documented
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Clinical Note
moderateThiotepa + Digoxin
"Thiotepa may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThiotepa + Digitoxin
"Thiotepa may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThiotepa + Deslanoside
"Thiotepa may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThiotepa + Acetyldigitoxin
"Thiotepa may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1.5-4.5 hours. Clinically, due to rapid clearance, dosing intervals are typically every 1-4 weeks.
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Primarily renal; 60-70% excreted unchanged in urine within 24-72 hours. Minor biliary/fecal elimination accounts for <10%.
Category C
Category D/X
Alkylating Agent
Alkylating Agent